Fujifilm: A Second Foundation Custom Case Solution & Analysis

1. Evidence Brief: Business Case Data Researcher

Financial Metrics

• Market Collapse: Global demand for photographic film peaked in 2000 and declined by approximately 10 percent annually, eventually losing 90 percent of its volume within a decade.
• Revenue Exposure: At the peak in 2000, photographic film accounted for 60 percent of Fujifilms total sales and approximately 70 percent of its operating profit.
• Restructuring Costs: The company recorded 3.3 billion dollars in restructuring charges between 2005 and 2006 to downsize the imaging segment.
• R and D Investment: Annual research and development spending was maintained at approximately 1.5 billion dollars during the crisis years to facilitate diversification.
• Profit Recovery: By 2007, operating income reached 1.7 billion dollars, surpassing the previous record set during the film peak.

Operational Facts

• Technological Assets: Fujifilm possessed a library of 20,000 chemical compounds and expertise in oxidation, collagen, and thin-film coating.
• Workforce Management: The company reduced its imaging division headcount by 5,000 employees while shifting others to new business units.
• Diversification Segments: New operations included LCD materials (TAC film), medical imaging (digital radiography), and cosmetics (Astalift).
• Joint Venture: Fuji Xerox provided a stable revenue stream in office documents, contributing roughly 40 percent of total revenue during the transition.

Stakeholder Positions

• Shigetaka Komori (CEO): Architect of the Second Foundation. He emphasized that Fujifilm was a chemical company first and a film company second.
• Internal R and D Teams: Initially resistant to moving from film to unrelated sectors like cosmetics or pharmaceuticals.
• Investors: Concerned about the high capital expenditure required for diversification into crowded markets like healthcare.

Information Gaps

• Competitor Margins: Specific operating margins for competitors in the LCD film market are not detailed for benchmarking.
• Customer Acquisition Costs: The cost to acquire customers in the cosmetics segment compared to traditional photographic retail is absent.
• Post-Merger Integration: Detailed data on the integration success of smaller medical acquisitions is limited.

2. Strategic Analysis: Market Strategy Consultant

Core Strategic Question

How can a dominant industrial incumbent survive the total obsolescence of its primary product while maintaining its manufacturing identity and workforce stability?

Structural Analysis

The Resource-Based View (RBV) reveals that Fujifilms competitive advantage was not the film itself, but the underlying chemical processes. Film production requires extreme precision in coating and collagen management. These same capabilities are critical for LCD screens (which require protective films) and skin care (which relies on collagen and antioxidants). This transition represents a pivot from a product-defined strategy to a capability-defined strategy.

Strategic Options

Preliminary Recommendation

Fujifilm must pursue the Aggressive Diversification path. The survival of the firm depends on decoupling its technical capabilities from the dying film market. By repositioning as a diversified chemical and healthcare entity, the company can protect its high-margin manufacturing heritage while entering markets with longer product lifecycles than consumer electronics.

3. Implementation Roadmap: Operations and Implementation Planner

Critical Path

The transition must follow a strict sequence to ensure financial stability during the pivot:

• Phase 1: Cash Preservation (Months 1-12). Optimize the Fuji Xerox partnership to provide the liquidity needed for restructuring the imaging division.
• Phase 2: Capability Mapping (Months 6-18). Audit the 20,000-compound library to identify specific chemicals with applications in pharmaceutical delivery and LCD manufacturing.
• Phase 3: Market Entry (Months 12-36). Launch the Astalift cosmetic line and scale TAC film production for the growing flat-panel display market.

Key Constraints

• Cultural Inertia: The transition from a 70-year-old film culture to a multi-industry mindset requires significant internal re-education.
• Technical Transferability: Success depends on the assumption that film-based chemical expertise translates perfectly to medical and cosmetic applications.
• Capital Allocation: The 1.5 billion dollar R and D budget must be strictly governed to prevent over-investment in non-performing segments.

Risk-Adjusted Implementation Strategy

To mitigate the risk of market entry failure, Fujifilm should use a hybrid model of organic growth for cosmetics and inorganic growth (M and A) for medical imaging. This balances the speed of entry with the preservation of internal chemical knowledge. Contingency plans must include a trigger to exit the digital camera market if margins drop below 5 percent, reallocating that capital to the medical division.

4. Executive Review and BLUF: Senior Partner

BLUF

Fujifilm must execute the Second Foundation strategy immediately. The 90 percent decline in film demand is an existential threat that renders the legacy business model obsolete. By reclassifying the company as a specialty chemical entity, management can deploy existing technical assets into the LCD and healthcare sectors. The priority is to replace the 70 percent profit hole left by film with high-margin functional materials. The Fuji Xerox cash flow provides the necessary runway, but speed in R and D commercialization is the only path to long-term viability.

Dangerous Assumption

The most consequential unchallenged premise is that chemical expertise in film production grants a sustainable competitive advantage in the cosmetics and pharmaceutical industries. While the underlying science overlaps, the brand requirements, distribution channels, and regulatory hurdles in healthcare are fundamentally different from consumer film. The analysis assumes technical superiority will overcome these market barriers.

Unaddressed Risks

• LCD Market Volatility: Heavy reliance on TAC film for LCDs creates a new single-point-of-failure risk. If a substitute for TAC film emerges, Fujifilm will face a second collapse. (Probability: Medium; Consequence: High)
• Talent Drain: The massive restructuring and shift in focus may lead to the loss of top-tier chemical scientists who joined the company specifically for imaging work. (Probability: High; Consequence: Medium)

Unconsidered Alternative

The team did not fully evaluate a pure-play spin-off strategy. Separating the document solutions (Xerox) and functional materials divisions into independent companies could have unlocked shareholder value and allowed each entity to pursue capital structures better suited to their specific growth profiles, rather than maintaining a complex conglomerate structure.

Verdict

APPROVED FOR LEADERSHIP REVIEW